Subscribe To
PACB / Does Pacific Biosciences (PACB) Have the Potential to Rally 30.15% as Wall Street Analysts Expect?
PACB News
By Zacks Investment Research
October 31, 2023
PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View
PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system. more_horizontal
By Seeking Alpha
October 30, 2023
Pacific Biosciences of California, Inc. (PACB) Q3 2023 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Todd Friedman more_horizontal
By Zacks Investment Research
October 6, 2023
Three Reasons to Add PacBio (PACB) Stock to Your Portfolio
PacBio's (PACB) product development activities raise optimism about the stock. more_horizontal
By Zacks Investment Research
September 14, 2023
Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?
Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estima more_horizontal
By Seeking Alpha
September 10, 2023
Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market
Pacific Biosciences has a leading position within the fast-growing long-read DNA sequencer market. Moreover, it is expanding its high-accuracy long-re more_horizontal
By Zacks Investment Research
September 5, 2023
Here's Why You Should Retain PacBio (PACB) Stock for Now
PacBio's (PACB) product development activities raise optimism about the stock. more_horizontal
By Zacks Investment Research
August 9, 2023
PacBio (PACB) Inks Research Collaboration for Genome Sequencing
PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Rev more_horizontal
By Zacks Investment Research
August 3, 2023
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system. more_horizontal